Whole blood was collected for laboratory analysis of inflammatory and lipid markers. Tumor necrosis factor (TNF-α), high sensitivity c-reactive protein (hs-CRP), oxidized low-density lipoprotein (ox-LDL), Low-density lipoproteins (LDL), apolipoprotein-B (apo-B), and triglycerides were selected based on their biological roles in CVD.
TNF-α (R&D Systems, Minneapolis, MN), hs-CRP (BN-100 nephelmometer, Dade Behring, Deerfield, IN), and ox-LDL (Mercodia AB, Uppsala, Sweden) were assessed in blood plasma by ELISA following their respective manufacturers’ directions. Triglycerides, total cholesterol, and high-density lipoproteins (HDL) were measured on the Vitro 950 Chemistry Station (Ortho-Clinical Diagnostics, Raritan, NJ) as per the manufacturer’s directions. LDL was calculated based on the subtraction of HDL from the total cholesterol measurements. Apo-B was assessed on a protein analyzer as per the manufacturer (BN ProSpec System, Dade Behring).
TNF-α (R&D Systems, Minneapolis, MN), hs-CRP (BN-100 nephelmometer, Dade Behring, Deerfield, IN), and ox-LDL (Mercodia AB, Uppsala, Sweden) were assessed in blood plasma by ELISA following their respective manufacturers’ directions. Triglycerides, total cholesterol, and high-density lipoproteins (HDL) were measured on the Vitro 950 Chemistry Station (Ortho-Clinical Diagnostics, Raritan, NJ) as per the manufacturer’s directions. LDL was calculated based on the subtraction of HDL from the total cholesterol measurements. Apo-B was assessed on a protein analyzer as per the manufacturer (BN ProSpec System, Dade Behring).